Incidence and Management of CAR-T Neurotoxicity in Patients with Multiple Myeloma Treated with Ciltacabtagene Autoleucel in CARTITUDE Studies

In CARTITUDE-1, 5% of patients with multiple myeloma reported movement and neurocognitive treatment-emergent adverse events with ciltacabtagene autoleucel (cilta-cel), a B cell maturation antigen-targeted CAR T cell therapy.